Recombinant Biotinylated Human TROP-2 / TACSTD2 Protein, His-tag, Avitag™, 25 µg

Background
TROP-2 is a single-copy gene in human cells, and encodes a type-1 transmembrane glycoprotein which is over-expressed in various malignancies, also referred to as tumor associated calcium signal transducer 2 (TACSTD2), GA733-1 or M1S1. TROP-2 is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. Trop-1 and Trop-2 are homologous to serum IGF-II-binding proteins and appear as signal transducers. Thus, they likely represent novel cell-surface receptors and may play a role in regulating the growth of carcinoma cells.

Source
Recombinant Biotinylated Human TROP-2 protein, His,Avitag (TR2-H82E5) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Thr 274 (Accession # P09758-1).
Predicted N-terminus: Gln 31

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 31.6 kDa. The protein migrates as 42-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas"
Cardillo, Zalath, Arrojo et al
Oncotarget (2024) 15, 144-158
(2) "Antibody-Drug Conjugates in Triple Negative Breast Cancer"
Keskinkilic, Sacks
Clin Breast Cancer (2024)
(3) "Rescue of secretion of rare-disease-associated misfolded mutant glycoproteins in UGGT1 knock-out mammalian cells"
Tax, Guay, Pantalone et al
Traffic (2024) 25 (1), e12927
Showing 1-3 of 280 papers.